100 related articles for article (PubMed ID: 29317481)
21. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
22. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells.
Kang S; Park SY; Lee HJ; Yoo YH
Biochem Biophys Res Commun; 2010 Jun; 396(3):731-5. PubMed ID: 20451496
[TBL] [Abstract][Full Text] [Related]
23. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
24. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
Aydin C; Sanlioglu AD; Karacay B; Ozbilim G; Dertsiz L; Ozbudak O; Akdis CA; Sanlioglu S
Hum Gene Ther; 2007 Jan; 18(1):39-50. PubMed ID: 17187448
[TBL] [Abstract][Full Text] [Related]
25. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations.
Tsikalakis S; Chatziandreou I; Michalopoulos NV; Theodoropoulos GE; Sakellariou S; Korkolopoulou P; Patsouris E; Saetta AA
Pathol Res Pract; 2018 Jun; 214(6):826-834. PubMed ID: 29731264
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of TRAIL and its death receptors in cervical cancer.
Maduro JH; Noordhuis MG; ten Hoor KA; Pras E; Arts HJ; Eijsink JJ; Hollema H; Mom CH; de Jong S; de Vries EG; de Bock GH; van der Zee AG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):203-11. PubMed ID: 19695437
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
30. Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.
Micheau O
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498673
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients.
Salehi E; Vodjgani M; Massoud A; Keyhani A; Rajab A; Shafaghi B; Gheflati Z; Aboufazeli T
Iran J Immunol; 2007 Dec; 4(4):197-205. PubMed ID: 18057577
[TBL] [Abstract][Full Text] [Related]
32. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
Guillaume YC; Lethier L; André C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
[TBL] [Abstract][Full Text] [Related]
33. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
34. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
35. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
36. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
Park JW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
Thyroid; 2003 Dec; 13(12):1103-10. PubMed ID: 14751030
[TBL] [Abstract][Full Text] [Related]
37. DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B; Ma B; Yang S; Xing X; Gu R; Hu Y
Spine (Phila Pa 1976); 2009 Sep; 34(19):E677-81. PubMed ID: 19730199
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
[TBL] [Abstract][Full Text] [Related]
39. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
[TBL] [Abstract][Full Text] [Related]
40. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
